ATM and B-cell chronic lymphocytic leukemia: Moreover, both in vitro and in vivo studies have demonstrated that ATM-deficient lymphoid tumor cells, i.e., CLL and MCL, are sensitive to PARP inhibition, with data showing cytotoxicity as well as reduced tumor growth and prolonged survival in animal models [14–17].